The Dark Side: “Serialized, But Not Secure”

I sometimes hear of pharma executives pushing back on product security investments with a justification something along the lines of, “We’re serialized now, so counterfeiting shouldn’t be a big concern.” That assumption, while understandable, is an increasingly risky bet. It is a common misperception, perhaps, especially among those not familiar with the front lines of counter-illicit trade in the pharmaceutical industry, to equate regulatory compliance and its attendant technologies with ample protection. While serialization is necessary, it is definitely not sufficient to protect patients, products and reputations from counterfeiters.

Compliance Is Not Protection

Serialization requirements are in force or under development in more than 50 countries, driven by regulatory regimens such as the EU Falsified Medicines Directive and the U.S. Drug Supply Chain Security Act.¹ These frameworks emerged in response to legitimate concerns about patient safety, recall effectiveness and traceability across increasingly complex global supply chains. Their purpose was clear: improve visibility, enable verification and strengthen regulatory oversight.

What serialization was not designed to be is a comprehensive security control.

Yet pharmaceutical manufacturers have invested heavily, financially and operationally, in serialization programs. After years of implementation effort, system integration and compliance audits, it is tempting to believe that serialization also provides a meaningful defense against counterfeiting, diversion and tampering. In practice, that belief often creates a false sense of security. And false confidence is itself a risk.

What Serialization Does Well — and What It Doesn’t

Serialization performs well at what it was designed to do. It supports traceability, facilitates recalls and enables transaction verification within compliant supply chains. It generates vast volumes of data and satisfies regulatory expectations.

But serialization does not and cannot authenticate the physical product. It does not prevent copying. And it does not stop determined adversaries from exploiting gaps in the system.

This is where the illusion of end-to-end visibility emerges. Serialization creates data, but data are not insight. Many organizations collect millions of serial events without actively analyzing them for anomalies, duplication or risk signals. When a scanned code checks out, scrutiny often ends, even when it shouldn’t.

A 2D Data Matrix Is Not Secure

At its core, a serialized 2D data matrix is a label. It can be replicated and reused. Industry and academic analyses have long warned that counterfeiters can duplicate legitimate serialized codes and apply them to fake packaging. If a counterfeit product bearing a copied code is scanned before the authentic product (or even after, depending on various factors), the system may signal it is legitimate, even when it is not.²

Criminals understand this dynamic well. They do not need to defeat serialization; they simply need to exploit system vulnerabilities. They exploit gaps in process implementation, real-world supply-chain practices (and failures thereof) and the fact that some systems permit repeated scans to avoid operational friction. They also exploit areas in which serialized controls are less effective, such as product returns processes. As multiple studies have shown, counterfeiters can adapt quickly to new standards and vulnerable or “breakable” technologies.³

The Risk of Believing You’re Protected

Brand-protection practitioners know from experience that genuine serial codes have appeared on counterfeit packaging many times, rarely publicized but frequently encountered. Experts have cautioned that treating serialization as an anticounterfeiting solution risks underestimating the sophistication of illicit trade networks and overestimating the protection serialization actually provides.⁴ This does not mean serialization has failed in this regard. It means it has sometimes been miscast.

Serialization is a regulatory compliance mechanism, not a security control. Treating it as the latter encourages complacency and delays investment in complementary safeguards.

Security Must Be Layered

Effective brand protection requires obstacles and friction for the adversary. That means layering controls across physical, digital, operational and organizational dimensions. Digital authentication technologies—particularly those that verify intrinsic or forensic features rather than printed identifiers—can play an important role as a robust security layer. But technology alone is insufficient.

A resilient program also requires governance, strategy, intelligence, investigative capability and clear response mechanisms. Detection without response is theater. Data without analysis is noise. Compliance without strategy is complacency.

The Right Question

Serialization is here to stay, and rightly so. It is a foundational element of modern pharmaceutical supply chains. But in terms of protecting patients and supply chain integrity, it should be treated as a starting point, not a finish line. The real question for pharmaceutical manufacturers is not “Are we compliant?” but “Are we meaningfully harder to counterfeit?”

Answering that question honestly is where real security begins.

References
1. 2025 global serialization regulations in the pharmaceutical industry. Softgroup. Accessed March 10, 2026. https://www.softgroup.eu/serialization-and-pharmaceutical-industry/

2. Fighting counterfeit pharmaceuticals: new defenses for an underestimated — and growing — menace. Strategy&. Accessed March 10, 2026. https://www.strategyand.pwc.com/gx/en/insights/2017/counterfeit-pharmaceuticals.html

3. Mapping global trade in fakes 2025. OECD/EUIPO. May 7, 2025. Accessed March 10, 2026. https://www.oecd.org/en/publications/mapping-global-trade-in-fakes-2025_94d3b29f-en.html

4. Chaudhuri A. The myth of drug traceability in India. Express Pharm. September 9, 2025. Accessed March 10, 2026. https://www.expresspharma.in/the-myth-of-drug-traceability-in-india/